

Financial Statements and Supplementary  
Information Together with  
Report of Independent Certified Public Accountants

**THE G. UNGER VETLESEN FOUNDATION**

For the year ended December 31, 2017

# THE G. UNGER VETLESEN FOUNDATION

## TABLE OF CONTENTS

---

	<b>Page</b>
Report of Independent Certified Public Accountants	1 - 2
Financial Statements:	
Statement of Assets and Net Assets Arising from Cash Transactions as of December 31, 2017	3
Statement of Cash Receipts, Disbursements and Change in Net Assets for the year ended December 31, 2017	4
Notes to Financial Statements	5 - 9
Supplementary Information:	
Supplemental Schedule of Marketable Securities as of December 31, 2017 and 2016 and for the year ended December 31, 2017	11



Grant Thornton LLP  
757 Third Avenue, 9th Floor  
New York, NY 10017  
T 212.599.0100  
F 212.370.4520  
[GrantThornton.com](http://GrantThornton.com)  
[linkd.in/GrantThorntonUS](https://www.linkedin.com/company/grantthorntonus)  
[twitter.com/GrantThorntonUS](https://twitter.com/GrantThorntonUS)

## REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

To the Board of Directors of  
**The G. Unger Vetlesen Foundation:**

### **Report on the financial statements**

We have audited the accompanying financial statements of The G. Unger Vetlesen Foundation (the “Foundation”), which comprise the statement of assets and net assets arising from cash transactions as of December 31, 2017, and the related statement of cash receipts, disbursements and change in net assets for the year then ended, and the related notes to the financial statements.

### **Management’s responsibility for the financial statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with the cash basis of accounting described in Note 2; this includes determining that the cash basis of accounting is an acceptable basis for the preparation of the financial statements in the circumstances. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor’s responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Foundation’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### **Opinion**

In our opinion, the financial statements referred to above present fairly, in all material respects, the assets and net assets arising from cash transactions of The G. Unger Vetlesen Foundation as of December 31, 2017, and its cash receipts, disbursements and change in net assets for the year then ended in accordance with the cash basis of accounting described in Note 2.

### **Basis of accounting**

We draw attention to Note 2 of the financial statements, which describes the basis of accounting. The financial statements are prepared on the cash basis of accounting, which is a basis of accounting other than accounting principles generally accepted in the United States of America. Our opinion is not modified with respect to this matter.

### **Supplementary Information**

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The Supplemental Schedule of Marketable Securities as of December 31, 2017 and 2016 and for the year ended December 31, 2017 on page 11 is presented for purposes of additional analysis and is not a required part of the financial statements. Such supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures. These additional procedures included comparing and reconciling the information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America established by the American Institute of Certified Public Accountants. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the financial statements as a whole.

*Grant Thornton LLP*

New York, New York  
June 25, 2018

**THE G. UNGER VETLESEN FOUNDATION**  
**Statement of Assets and Net Assets Arising from Cash Transactions**  
**As of December 31, 2017**

---

**ASSETS**

Cash and cash equivalents:

JPMorgan Chase checking account	\$ 984
Deutsche Bank custody, checking and money market accounts	1,033,626
First Republic Bank checking account	<u>136,977</u>
	1,171,587

Marketable securities, at cost (Note 3):

Common stocks (fair value \$146,926,850)	<u>50,333,677</u>
--	-------------------

Net assets - unrestricted \$ 51,505,264

*The accompanying notes are an integral part of this financial statement.*

**THE G. UNGER VETLESEN FOUNDATION**  
**Statement of Cash Receipts, Disbursements and Change in Net Assets**  
**For the year ended December 31, 2017**

---

CASH RECEIPTS

Dividends:

Common stock \$ 2,415,387

Interest:

Deutsche Bank money market account 21,289

Net realized gain on sale of marketable securities 2,801,805

Total receipts 5,238,481

CASH DISBURSEMENTS

Grants (Note 4) 6,531,092

General and administrative expenses and taxes 668,329

Total disbursements 7,199,421

Change in net assets - deficiency in cash receipts over disbursements (1,960,940)

Net assets, beginning of year 53,466,204

Net assets, end of year \$ 51,505,264

*The accompanying notes are an integral part of this financial statement.*

**THE G. UNGER VETLESEN FOUNDATION**  
**Notes to Financial Statements**  
**December 31, 2017**

---

**1. BUSINESS AND TAX STATUS**

The G. Unger Vetlesen Foundation (the “Foundation”) was incorporated on March 7, 1955, under the laws of the State of New York, as a nonprofit membership corporation for voluntarily aiding and contributing to religious, charitable, scientific, literary and educational uses and purposes, in New York, elsewhere in the United States and throughout the world. The funds of the Foundation may be expended for the purposes and objectives stated.

The Foundation is a tax-exempt organization pursuant to Section 501(c)(3) of the Internal Revenue Code, and, accordingly, is not subject to federal income tax. However, the Foundation is classified as a private foundation and, therefore, is subject to an annual federal excise tax not to exceed 2% on net investment income including dividends, interest and net realized gains on securities transactions, reduced by related expenses.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Presentation**

The financial statements and accounts of the Foundation are prepared on the basis of cash receipts and disbursements, which is a comprehensive basis of accounting other than accounting principles generally accepted in the United States of America (“US GAAP”); consequently, certain revenues, principally investment income, and related assets are recognized when received and expenses are recognized when paid. Under US GAAP, revenues and assets are accrued when earned and expenses and liabilities are recognized when the obligations are incurred. In addition, the Foundation reports marketable securities at cost rather than at fair value. Under US GAAP, marketable securities are reported at fair value.

**Cash and Cash Equivalents**

Cash and cash equivalents consist of bank checking accounts and money market funds. The Foundation considers all highly liquid financial instruments, with original maturities of three months or less from the date of purchase, to be cash equivalents.

**Concentrations of Credit Risk**

Cash and cash equivalents and investments are exposed to various risks, such as interest rate, market and credit. To minimize such risks, the Foundation has a diversified portfolio reviewed or managed by independent investment managers in a variety of asset classes. The Foundation regularly evaluates its investments including performance thereof. Due to inherent risks and potential volatility in investment valuations, the amounts reported in the accompanying financial statements can vary substantially from year to year. The Foundation maintains its cash and cash equivalents in various bank deposit accounts which, at times, may exceed federally insured limits. The Foundation’s cash accounts were placed with high credit quality financial institutions and, accordingly, the Foundation does not expect nonperformance.

**Financial Statement Presentation**

All assets and income are unrestricted as they are neither permanently or temporarily restricted by donor-imposed restrictions, and, therefore, are available for general operations of the Foundation.

**THE G. UNGER VETLESEN FOUNDATION**  
**Notes to Financial Statements**  
**December 31, 2017**

---

**3. MARKETABLE SECURITIES**

Marketable securities are carried at cost in the accompanying financial statements. The cost basis of securities received from the Estate of Georg Unger Vetlesen and the Palaemona Lyster Smythe Trust was determined based upon the related fair values as of the dates received, May 11, 1959 and January 3, 1985, respectively. The cost of securities sold is determined on the first-in, first-out-cost basis.

The fair values of marketable securities are based on published closing prices on December 31, 2017. Changes in fair values of the marketable securities will affect future grants. At December 31, 2017, concentrations in marketable securities (5% or more of total fair value of marketable securities) included the following common stock investments at quoted market values:

Ametek, Inc.	\$ 8,560,519
Celgene Corp.	10,957,800
Exxon Mobil Corp.	8,364,000
JPMorgan Chase & Co.	9,483,439
Merck & Co. Inc.	7,877,800
Murphy Oil Corp.	11,022,750
Roper Industries, Inc.	8,806,000
Thermo Fisher Scientific, Inc.	7,595,200
Union Pacific Corp.	<u>10,728,000</u>
	<u>\$ 83,395,508</u>

Since the financial statements of the Foundation are prepared on the basis of cash receipts and disbursements and therefore marketable securities recorded at cost rather than at fair value, the Foundation has not applied the guidance relating to "Fair Value Measurements," to its financial statements, however, this guidance is still relevant for disclosure purposes. This guidance establishes a framework for measuring fair value, expands disclosures about fair value measurements and provides a consistent definition of fair value, which focuses on an exit price between market participants in an orderly transaction. The guidance also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes a three-level hierarchy for fair value measurements based on the transparency of information used in the valuation of an asset or liability as of the measurement date. Assets and liabilities measured and reported at fair value are classified and disclosed in one of the following categories:

- Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The type of investments in Level 1 include listed equities held in the name of the Foundation, and exclude listed equities and other securities held indirectly through commingled funds.



**THE G. UNGER VETLESEN FOUNDATION**  
**Notes to Financial Statements**  
**December 31, 2017**

---

Level 2 - Pricing inputs, including broker quotes, are generally those other than exchange quoted prices in active markets, which are either directly or indirectly observable as of the measurement date, and fair value is determined through the use of models or other valuation methodologies.

Level 3 - Pricing inputs are unobservable for the assets or liabilities and include situations where there is little, if any, market activity for the assets or liabilities. The inputs into the determination of fair value require significant management judgment or estimation.

In accordance with relevant guidance, the Foundation excludes investments valued using net asset value (“NAV”) per share as a practical expedient from classification within the fair value hierarchy. The Foundation did not hold any investments valued at NAV per share as of December 31, 2017.

Inputs are used in applying the various valuation techniques and broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics, and other factors. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes “observable” requires significant judgment by the Foundation. The Foundation considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the Foundation’s perceived risk of that instrument. As of December 31, 2017, all of the Foundation’s investments were Level 1.

**4. GRANTS**

Grants paid in 2017 were as follows:

<b>Organization</b>	<b>Purpose</b>	<b>Amount</b>
American-Scandinavian Foundation	General purposes	\$ 25,000
Atlantic Salmon Federation	General purposes	25,000
Atlantic Salmon Trust	General purposes	25,000
BIOS - Bermuda Institute for Ocean Sciences (formerly Bermuda Biological Station for Research)	General purposes	150,000
Bigelow Laboratories for Ocean Sciences	General purposes	100,000
Black Rock Consortium	\$50,000 for general purposes and \$100,000 for postdoctoral fellowship in ecological science	150,000
Bonefish & Tarpon Trust	General purposes	25,000
Catholic Charities USA	Disaster relief	50,000
Cape Eleuthera School	General purposes	50,000
Chesapeake Bay Foundation	\$25,000 for general purposes and \$50,000 for oyster restoration project	75,000

**THE G. UNGER VETLESEN FOUNDATION**  
**Notes to Financial Statements**  
**December 31, 2017**

Organization	Purpose	Amount
Colorado State University, Department of Atmospheric Science	Research on Global Temperature and Atlantic Hurricanes	\$ 100,000
Columbia University, Lamont-Doherty Earth Observatory	\$400,000 for general purposes, \$100,000 for the programs of the Climate Center, and \$28,592 for the 2017 Vetlesen Prize	528,592
Connecticut Fund for the Environment	Save the Sound Program	50,000
Doctors Without Borders Foundation Center	International medical relief program	50,000
Gulf of Maine Research Institute	Membership	2,500
International Yacht Restoration School	Fishing gear technologist position	100,000
Marine Biological Laboratories	General purposes	25,000
Massachusetts Institute of Technology	General purposes of the Bay Paul Center	350,000
National Parks Conservation Association	Joint Program on the Science and Policy of Global Change	100,000
Oregon State University, College of Oceanic & Atmospheric Sciences	General purposes	25,000
Organization for Tropical Studies	General purposes	300,000
Peregrine Fund	\$75,000 for general purposes and \$125,000 for Campaign for OTS	200,000
Resources for the Future	General purposes	100,000
Rutgers University, Institute of Marine and Coastal Sciences	Climate Economics and Policy Program	50,000
Scenic Hudson	General purposes	100,000
Texas A&M University, Geochemical and Environmental Group	Riverfront Communities Program and/or Ecological Restoration Initiatives	75,000
University of British Columbia	General purposes	50,000
University of California, Scripps Institution of Oceanography	\$50,000 for research on oceanic dead zones and \$50,000 for research on impact of climate change and fisheries on salmon	100,000
University of Florida, Whitney Laboratory	Global Change Program	600,000
University of Maryland, Institute of Marine and Environmental Technology	General purposes	100,000
University of Miami, Rosenstiel School of Marine and Atmospheric Science	General purposes	100,000
University of Rhode Island, Graduate School of Oceanography	Climate studies at the Rosenstiel School of Marine and Atmospheric Sciences	300,000
University of Texas, Institute for Geophysics	\$250,000 for general purposes and \$125,000 for purchase of research catamaran	375,000
University of Virginia, Department of Environmental and Civil Engineering	Antarctic aerogeophysical research project	300,000
University of Washington, College of the Environment	Research on wastewater treatment and algae cultivation	50,000
Webb Institute	\$300,000 for the general purposes of the School of Oceanography and \$25,000 for Dr. Laidre's work on whales in Greenland	325,000
Wildlife Conservation Society	\$50,000 for general purposes and \$100,000 for capital campaign	150,000
Woods Hole Oceanographic Institution	\$50,000 for the Global Health Program, \$50,000 for Marine Mammal and Veterinary Programs, \$100,000 for general purposes, and \$250,000 for Molecular Program	450,000
Yellowstone Park Foundation	General purposes	750,000
	General purposes	50,000
<b>TOTAL GRANTS</b>		<b><u>\$ 6,531,092</u></b>

**THE G. UNGER VETLESEN FOUNDATION**  
**Notes to Financial Statements**  
**December 31, 2017**

---

At December 31, 2017, the Foundation does not have any commitments to make future grants.

**5. RELATED PARTY TRANSACTIONS**

Individual members of the Foundation's Board of Directors serve on the boards of directors or similar boards of a number of its grantees, including the Wildlife Conservation Society and the Peregrine Fund. None of the directors receive any compensation for their services as such.

**6. SUBSEQUENT EVENTS**

The Foundation evaluated its December 31, 2017 financial statements for subsequent events through June 25, 2018, the date the financial statements were available to be issued. The Foundation is not aware of any subsequent events that would require recognition or disclosure in the financial statements.

**SUPPLEMENTARY INFORMATION**

**THE G. UNGER VETLESEN FOUNDATION**  
**Supplemental Schedule of Marketable Securities**  
**As of December 31, 2017 and 2016 and for the year ended December 31, 2017**

Common Stocks	Held at December 31, 2016		Additions		Sales and Other Dispositions				Held at December 31, 2017			
	Shares or Principal Amount	Cost Basis	Shares or Principal Amount	Cost Basis	Shares or Principal Amount	Cost Basis	Proceeds	Gain (Loss)	Shares or Principal Amount	Cost Basis	Fair Value 12/31/2017	Dividends Received in 2017
Align Technology	-	\$ -	6,500	\$ 1,124,843	-	\$ -	\$ -	\$ -	6,500	\$ 1,124,843	\$ 1,444,235	\$ -
Allergan	9,000	2,060,056	-	-	-	-	-	-	9,000	2,060,056	1,472,220	25,200
American Tower Corp CL A REIT	40,000	1,696,777	-	-	-	-	-	-	40,000	1,696,777	5,706,800	102,060
Ametek Inc.	118,125	1,608,102	-	-	-	-	-	-	118,125	1,608,102	8,560,519	42,525
Bank of America Corp.	52,000	1,970,800	-	-	-	-	-	-	52,000	1,970,800	1,535,040	20,280
Biogen	3,100	985,490	-	-	3,100	905,755	787,805	(117,950)	-	-	-	-
Biomarin Pharmaceutical Inc.	25,000	2,174,093	-	-	-	-	-	-	25,000	2,174,093	2,229,250	-
Bioerativ	-	-	-	-	-	-	-	-	1,550	79,735	83,576	-
Boeing Company	15,000	2,053,898	-	-	-	-	-	-	15,000	2,053,898	4,423,650	85,200
BP Amoco PLC ADR	22,800	319,273	-	-	-	-	-	-	22,800	319,273	958,284	54,492
Bristol Meyers Squibb Co	20,000	1,002,400	-	-	20,000	1,002,400	1,091,867	89,467	-	-	-	23,400
Celgene Corp.	120,000	1,186,017	-	-	15,000	195,707	1,481,789	1,286,082	105,000	990,310	10,957,800	-
Citigroup Inc.	2,410	609,854	-	-	-	-	-	-	2,410	609,854	179,328	2,314
Continental Resources Inc.	36,000	1,314,180	-	-	36,000	1,314,180	1,226,387	(87,793)	-	-	-	-
Cooper Co	16,000	2,135,750	-	-	-	-	-	-	16,000	2,135,750	3,486,080	960
Deltic Timber Corp.	52,285	357,190	-	-	-	-	-	-	52,285	357,190	4,786,692	20,914
Envision Healthcare Corp	-	-	30,000	2,085,981	-	-	-	-	30,000	2,085,981	1,036,800	-
EOG Res Inc.	20,000	974,847	-	-	-	-	-	-	20,000	974,847	2,158,200	13,400
Exxon Mobil Corp.	100,000	381,310	-	-	-	-	-	-	100,000	381,310	8,364,000	306,000
Gilead Sciences Inc.	75,000	981,776	-	-	10,000	130,903	749,018	618,115	65,000	850,873	4,656,600	150,800
Global Payments Inc	-	-	10,500	1,013,357	-	-	-	-	10,500	1,013,357	1,052,520	233
Idexx Corp	-	-	6,000	1,004,186	-	-	-	-	6,000	1,004,186	938,280	-
International Flavors & Fragrances	13,559	7,642	-	-	-	-	-	-	13,559	7,642	2,069,239	35,389
JPMorgan Chase & Co.	88,680	1,909,796	-	-	-	-	-	-	88,680	1,909,796	9,483,439	180,907
McKesson Corp	25,000	2,955,875	-	-	25,000	2,955,875	3,468,794	512,919	-	-	-	7,000
Mead Johnson Nutrition Co	9,900	750,173	-	-	9,900	750,173	881,920	131,747	-	-	-	8,168
Merck & Co. Inc.	150,000	185,350	-	-	10,000	12,357	599,689	587,332	140,000	172,993	7,877,800	282,000
Microsoft Corp.	29,000	757,190	-	-	-	-	-	-	29,000	757,190	2,480,660	46,110
Monsanto Co.	60,000	1,208,438	-	-	-	-	-	-	60,000	1,208,438	7,006,800	129,600
Murphy Oil Corp.	355,000	1,173,137	-	-	-	-	-	-	355,000	1,173,137	11,022,750	355,000
Nvidia Corp	-	-	3,600	493,281	-	-	-	-	3,600	493,281	696,600	1,044
Owens Illinois Inc.	20,000	662,730	-	-	20,000	662,730	444,616	(218,114)	-	-	-	-
Parker Hannifin Corp	25,000	2,488,518	-	-	-	-	-	-	25,000	2,488,518	4,989,500	66,000
Pfizer Inc.	104,408	3,600,262	-	-	-	-	-	-	104,408	3,600,262	3,781,658	133,642
Pinnacle Foods	30,000	1,477,110	7,000	379,439	-	-	-	-	37,000	1,856,549	2,200,390	41,665
Roper Industries Inc	34,000	4,243,219	-	-	-	-	-	-	34,000	4,243,219	8,806,000	47,600
Shire PLC	12,000	2,243,869	-	-	-	-	-	-	12,000	2,243,869	1,861,440	11,084
Stericycle Inc.	25,000	1,314,985	-	-	-	-	-	-	25,000	1,314,985	1,699,750	-
Supernus Pharmaceuticals Inc	-	-	15,000	736,290	49	-	-	-	14,951	736,290	597,750	-
Thermo Fisher Scientific, Inc.	40,000	3,360,203	-	-	-	-	-	-	40,000	3,360,203	7,595,200	24,000
Union Pacific Corp.	80,000	1,276,070	-	-	-	-	-	-	80,000	1,276,070	10,728,000	198,400
Total marketable securities		<u>\$ 51,426,380</u>		<u>\$ 6,837,377</u>		<u>\$ 7,930,080</u>	<u>\$ 10,731,885</u>	<u>\$ 2,801,805</u>		<u>\$ 50,333,677</u>	<u>\$ 146,926,850</u>	<u>\$ 2,415,387</u>

*This supplemental schedule should be read in conjunction with the accompanying financial statement and notes thereto.*